PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 963
- Registration Number
- NCT00911937
- Locations
- 🇺🇸
Pfizer Investigational Site, Menomonee Falls, Wisconsin, United States
The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects
Phase 1
Completed
- Conditions
- Overactive Bladder With Symptoms of Frequency, Urgency, and Urge Urinary Incontinence
- Interventions
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2011-06-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 28
- Registration Number
- NCT00911235
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Effects of Etanercept on the Heart, Veins and Thickness of Certain Major Arteries In Ankylosing Spondylitis Patients
- First Posted Date
- 2009-05-29
- Last Posted Date
- 2016-01-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 34
- Registration Number
- NCT00910273
- Locations
- 🇮🇹
Pfizer Investigational Site, Roma, Italy
Study Of The Effect Of CP-751,871 In Combination With Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer
Phase 3
Withdrawn
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2009-05-22
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00907504
A Phase 1 Trial To Assess The Safety And Pharmacokinetics Of Single, Ascending, Oral Doses Of Dimebon In Healthy Adults
- First Posted Date
- 2009-05-22
- Last Posted Date
- 2009-07-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00907322
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
Study Evaluating Severe Surgical Site Infections (SSIs) Following Contaminated Or Dirty-infected Abdominal Surgery
Completed
- Conditions
- Surgical Wound InfectionPostoperative Wound Infection
- Interventions
- Procedure: Elective or emergency abdominal surgery
- First Posted Date
- 2009-05-21
- Last Posted Date
- 2012-05-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 180
- Registration Number
- NCT00906074
A Bioequivalence Study Of AG-013736 Tablets In Healthy Volunteers
- First Posted Date
- 2009-05-21
- Last Posted Date
- 2009-11-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00905814
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Phase 3
Completed
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-05-20
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 45
- Registration Number
- NCT00904670
- Locations
- 🇺🇸
UC Irvine Child Development Center, Irvine, California, United States
🇺🇸Center for Psychiatry and Behavioral Medicine, Incorporated, Las Vegas, Nevada, United States
A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT00902187
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
A Study Of Early Markers Of Choroidal Neovascularization
Terminated
- Conditions
- Choroidal Neovascularization (CNV)Age-related Macular Degeneration (AMD)Early Markers
- Interventions
- Other: no drug
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2010-11-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT00902785
- Locations
- 🇬🇧
Pfizer Investigational Site, Belfast, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath